Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi gets binding bids for consumer unit
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business.
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners,
Sanofi reportedly gets PE bids for consumer health unit
French pharma giant Sanofi received binding offers for its consumer health business from private equity firms PAI Partners and Clayton Dubilier & Rice, with expectations that a deal would be worth at least €15 billion,
Sanofi gets binding bids for consumer unit: Bloomberg News
Private equity firms Clayton Dubilier & Rice and PAI Partners have forwarded binding bids for Sanofi’s (NASDAQ:SNY) consumer health division as the French pharma giant looks to sell the unit in one of Europe’s biggest deals this year,
5d
on MSN
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
STAT
8d
Amid push to redefine itself, Sanofi names new chief scientific officer
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
5d
CD&R Excludes Debt-Funded Equity Option From Final Sanofi Bid
Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of ...
5d
on MSN
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
5d
Sanofi blockbuster drug wins clearance in US for lung disease
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
FiercePharma
5d
Sanofi, Regeneron look to seize major opportunity with Dupixent's COPD approval
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
9d
Sanofi CEO believes company poised for growth from new drugs
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
7d
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company ...
FiercePharma
5d
After Sanofi's first-line myeloma nod, J&J strikes back with new tranche of Darzalex data
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
globalconstructionreview
2d
France’s Sanofi to build €1.3bn insulin plant in Germany
French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...
3d
on MSN
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Regeneron
Dupixent
COPD
United States
Chronic obstructive pulmonary disease
Feedback